Update on Tildrakizumab for Psoriasis

This article will review recent publications on tildrakizumab to evaluate its pharmacokinetics, efficacy, and safety.Recent FindingsTildrakizumab maintains efficacy in moderate-to-severe plaque psoriasis for up to 3  years with low risk of adverse events.SummaryIL-23p19 inhibition with tildrakizumab is a useful therapy for treating moderate-to-severe psoriasis. It is superior to placebo and etanercept in clinical trials as measured by Psoriasis Area Severity Index (PASI), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) scores. Clinical improvements are maintained for up to 3  years. It has a low frequency of adverse events that is similar to placebo, with the most common being headache and nasopharyngitis. Tildrakizumab can be a useful therapeutic option for patients with plaque psoriasis resistant to phototherapy and other systemic medications.
Source: Current Dermatology Reports - Category: Dermatology Source Type: research